Alseres Pharmaceuticals, Inc.
ALSE · OTC
6/30/2014 | 3/31/2014 | 12/31/2013 | 9/30/2013 | |
|---|---|---|---|---|
| Market Cap | $996 | $1,235 | $720 | $1,838 |
| - Cash | $46 | $94 | $114 | $27 |
| + Debt | $8,416 | $8,129 | $7,820 | $6,685 |
| Enterprise Value | $9,365 | $9,270 | $8,426 | $8,496 |
| Revenue | $18 | $18 | $418 | $18 |
| % Growth | 0% | -95.6% | 2,170.1% | – |
| Gross Profit | $18 | $18 | $395 | $18 |
| % Margin | 95% | 95% | 94.3% | 100% |
| EBITDA | -$317 | -$331 | $356 | -$296 |
| % Margin | -1,720.5% | -1,793.9% | 85.1% | -1,605.9% |
| Net Income | -$321 | -$332 | $239 | -$363 |
| % Margin | -1,741.5% | -1,801.3% | 57.1% | -1,969.4% |
| EPS Diluted | -52.39 | -54.19 | 50 | -50 |
| % Growth | 3.3% | -208.4% | 200% | – |
| Operating Cash Flow | -$272 | -$385 | -$386 | -$301 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$272 | -$385 | -$386 | -$301 |